

## CLINICAL VIGNETTE

# Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma – A Rare and Aggressive Variant

Amy Chow, M.D.

### *Introduction*

Papillary thyroid carcinoma is the most frequent type of thyroid carcinoma. It is divided into many variants with variable clinicopathological characteristics and biological behaviors.<sup>1</sup> Most variants, especially classic papillary thyroid carcinoma, are indolent and the 5 years' survival of patients is reported to be 95-98%.<sup>2</sup> However, diffuse sclerosing variant of papillary thyroid cancer is rare and more aggressive than classic papillary thyroid cancer. The aim of this case report is to present a case of diffuse sclerosing variant papillary thyroid cancer.

### *Case Presentation*

A 25-year-old woman with hypothyroidism secondary to Hashimoto's thyroiditis for more than 6 years, undifferentiated connective tissue disorder and vitiligo presented for evaluation of goiter. She was in her usual state of health until four months prior to the office visit when she noticed increasing neck swelling, worsening dysphagia, and intermittent hoarseness of the voice. Ultrasound of the thyroid four months ago showed a goiter with diffuse heterogeneous background and increased blood flow, without nodule or calcification or abnormal cervical lymph nodes. She had no prior radiation exposure. She was adopted and her adopted mother died from papillary thyroid cancer. She takes thyroxine 100 mcg/day with normal TSH of 2.4 U/ml. Her thyroid exam showed symmetrically enlarged lobes, without discrete nodules, calcification and no palpable cervical lymph nodes.

A repeat thyroid ultrasound showed similar sized goiter with diffuse heterogeneous background without any nodule or abnormal cervical lymph node or calcification (right lobe is 1.7 cm x 1.9 cm x 5.3 cm, left lobe is 1.9 cm x 1.8 cm x 4.8 cm and isthmus is 1.0 cm).

Due to worsening compressive symptoms, patient underwent total thyroidectomy. The surgical pathology showed right lobe papillary thyroid cancer, diffuse sclerosing variant. The cancer size was at least 2.0 cm with lymph vascular invasion but had no extra thyroidal extension.

Patient underwent 104.9mCi of Iodine-131 therapy. The post treatment scan showed excellent response to therapy (< 1% uptake in the thyroid bed). She had been taking levothyroxine 175 mcg daily after the surgery.

### *Discussion*

Diffuse sclerosing variant of the papillary thyroid cancer (DSVPTC) was first described in 1985.<sup>3</sup> It is reported to account for about 0.7 to 6.6% of all papillary thyroid carcinomas. Higher prevalence of DSVPTC was noted in pediatric patients and in patients affected by irradiation. DSVPTC tends to occur more frequently in women and patients in the third decade of life.<sup>4</sup>

Most patients present with diffuse goiter and are clinical euthyroid but can be hypothyroid or hyperthyroid. Most patients have cervical lymph node metastasis at the time of the diagnosis.<sup>5</sup> Lung metastasis<sup>6</sup> and cerebral metastasis at presentation have also been reported.<sup>7</sup> Distant metastases may present in up to 5% of the cases.<sup>4</sup> DSVPTC can present as numerous diffuse microcalcifications in Hashimoto's thyroiditis<sup>8</sup> or can mimic benign Riedel's thyroiditis.<sup>9</sup>

The ultra-sonographic appearance of the DSVPTC may show diffusely altered thyroid parenchyma with a snow-storm appearance and generally firm enlarged thyroid lobes with diffusely prominent microcalcifications and psammoma bodies.<sup>8</sup> DSVPTC can involve the thyroid gland extensively without forming a dominant mass.<sup>4</sup>

If there is suspicious nodule on the thyroid ultrasound, a fine needle aspiration biopsy is the most valuable diagnostic procedure for pre-discrimination of the benign and malignant nodules. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive for diagnosing aggressive variants of papillary thyroid carcinoma.<sup>10</sup>

DSVPTC is characterized by histologic features such as numerous psammoma bodies; extensive lymphocytic infiltration; squamous metaplasia; diffuse fibrosis; calcification and absence of string colloids together with the characteristic cytoarchitectural pattern of classic papillary carcinoma. The diagnosis of DSVPTC is challenging because it may be mistaken clinically for benign disease, particular thyroiditis. A diagnosis of DSVPTC should be considered when above mentioned ultrasound feature and histological features are present.<sup>11</sup>

The molecular profile of DSVPTC is different from classic papillary thyroid cancer. The immunohistochemical studies of DSVPTC showed different expression pattern of epithelial

membrane antigens; galectin 3, cell adhesion molecules, p53 and p63 when compared to classic papillary thyroid carcinoma.<sup>4</sup> Genetic analysis shows a different pattern of genetic mutation, activation of RET/PTC rearrange as the major genetic alteration in DSVPTC. RET/PTC3 rearrangement is associated with advanced stage at diagnosis and poor clinical outcomes.<sup>12</sup> The occurrence of thyroid cancer oncogenes BRAF and RAS mutations are uncommon events when compared to classic papillary thyroid cancer.<sup>4</sup>

Many studies showed DSVPTC is very aggressive and has a less favorable outcome than classic papillary thyroid cancer.<sup>13</sup> A meta-analysis showed DSVPTC has higher rate of cancer multifocality, vascular invasion, extrathyroidal extension, lymph node metastasis, distant metastasis and is likely to recur. It has worsened overall survival compared to classic papillary thyroid cancer and should be considered as high-risk papillary thyroid cancer.<sup>14</sup> Another study showed the recurrent rate within first 5 years is high and requires a careful ongoing surveillance, similar to the follow up of high risk papillary thyroid cancer patients.<sup>15</sup>

The treatment is total thyroidectomy with lymph node excision followed by radioiodine therapy due to the aggressive biological behavior of DSVPTC.<sup>16</sup>

### Summary

DSVPTC has different clinical, pathological, and molecular profiles when compared to classic papillary thyroid cancer and requires more aggressive treatment and close monitoring. They may be mistaken for benign disease particularly thyroiditis. In this case, the clinical presentation, biochemical, and initial radiological findings were all indicative of benign pathology. It is important to consider this rare cancer when evaluating a young patient with goiter or Reidel's thyroiditis or Hashimoto's thyroiditis.

### REFERENCES

1. **DeLellis RA, Lloyd RV, Heitz PU, Eng G.** World Health Organization Classification of Tumours. *Pathology and Genetics of Tumours of Endocrine Organs*. Lyons, France: IARC Press; 2004.
2. **Clark OH.** Thyroid cancer and lymph node metastases. *J Surg Oncol*. 2011 May 1;103(6):615-8. doi: 10.1002/jso.21804. PubMed PMID: 21480256.
3. **Vickery AL Jr, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M.** Papillary carcinoma. *Semin Diagn Pathol*. 1985 May;2(2):90-100. PubMed PMID: 3843693.
4. **Pillai S, Gopalan V, Smith RA, Lam AK.** Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. *Crit Rev Oncol Hematol*. 2015 Apr;94(1):64-73. doi:10.1016/j.critrevonc.2014.12.001. Epub 2014 Dec 18. Review. PubMed PMID:25577570.
5. **McElvanna K, McCusker G, Stirling I.** Diffuse sclerosing variant of papillary thyroid carcinoma--a rare cause of goitre in a young patient. *Ulster Med J*. 2007 May;76(2):113-4. PubMed PMID: 17476829; PubMed Central PMCID: PMC2001140.
6. **Carcangiu ML, Bianchi S.** Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. *Am J Surg Pathol*. 1989 Dec;13(12):1041-9. PubMed PMID: 2490923.
7. **Imamura Y, Kasahara Y, Fukuda M.** Multiple brain metastases from a diffuse sclerosing variant of papillary carcinoma of the thyroid. *Endocr Pathol*. 2000 Spring;11(1):97-108. PubMed PMID: 15304844.
8. **Jeong SH, Hong HS, Lee EH, Kwak JJ.** The Diffuse Sclerosing Variant of Papillary Thyroid Cancer Presenting as Innumerable Diffuse Microcalcifications in Underlying Adolescent Hashimoto's Thyroiditis: A Case Report. *Medicine (Baltimore)*. 2016 Mar;95(12):e3141. doi: 10.1097/MD.0000000000003141. PubMed PMID: 27015194; PubMed Central PMCID: PMC4998389.
9. **Walsh J, Griffin TP, Ryan CB, Fitzgibbon J, Sheahan P, Murphy MS.** A Case Report Demonstrating How the Clinical Presentation of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Can Mimic Benign Riedel's Thyroiditis. *Case Rep Endocrinol*. 2015;2015:686085. doi: 10.1155/2015/686085. Epub 2015 Jun 2. PubMed PMID: 26137328; PubMed Central PMCID: PMC4468291.
10. **Evranos B, Polat SB, Baser H, Ozdemir D, Kilicarslan A, Yalcin A, Ersoy R, Cakir B.** Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma. *Cytopathology*. 2016 Sep 25. doi: 10.1111/cyt.12384. [Epub ahead of print] PubMed PMID: 27666595.
11. **Kumarasinghe MP.** Cytomorphologic features of diffuse sclerosing variant of papillary carcinoma of the thyroid. A report of two cases in children. *Acta Cytol*. 1998 Jul-Aug;42(4):983-6. PubMed PMID: 9684590.
12. **Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, Chung JH, Ki CS, Kim SW.** Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. *Histopathology*. 2016 Jul;69(1):45-53. doi: 10.1111/his.12902. Epub 2016 Jan 11. PubMed PMID:26568156.
13. **Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, Kim JS.** Follicular and Diffuse Sclerosing Variant Papillary Thyroid Carcinomas as Independent Predictive Factors of Loco-Regional Recurrence: A Comparison Study Using Propensity Score Matching. *Thyroid*. 2016 Aug;26(8):1077-84. doi: 10.1089/thy.2016.0113. PubMed PMID: 27324748.
14. **Vuong HG, Kondo T, Pham TQ, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R.** Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. *Eur J Endocrinol*. 2017 Apr;176(4):431-439. doi: 10.1530/EJE-16-0863. Review. PubMed PMID: 28183787.
15. **Chereau N, Giudicelli X, Pattou F, Lifante JC, Triponez F, Mirallié E, Goudet P, Brunaud L, Trésallet C, Tissier F, Leenhardt L, du Montcel ST, Menegaux F.** Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study. *J Clin Endocrinol Metab*.

2016 Dec;101(12):4603-4610. Epub 2016 Sep 14.  
PubMed PMID: 27626975.

16. **Malandrino P, Russo M, Regalbuto C, Pellegriti G, Moleti M, Caff A, Squatrito S, Vigneri R.** Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. *Thyroid*. 2016 Sep;26(9):1285-92. doi:10.1089/thy.2016.0168. Epub 2016 Jul 22. PubMed PMID: 27349273.

*Submitted April 11, 2017*